Ideaya Biosciences | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 8.857 M

Revenue: As of FY2026 Q2, the actual value is USD 8.857 M, beating the estimate of USD 7.447 M.

EPS: As of FY2026 Q2, the actual value is USD -1.22, missing the estimate of USD -1.0788.

EBIT: As of FY2026 Q2, the actual value is USD -112.45 M.

Financial Position and Cash Flow

IDEAYA Biosciences, Inc. reported cash, cash equivalents, and marketable securities of approximately $1.24 billion as of June 30, 2026, an increase from $972.9 million as of March 31, 2026, and $1.05 billion as of December 31, 2025. This increase was primarily driven by $323.4 million in net proceeds from a public offering and $33.1 million from an at-the-market offering, partially offset by net cash used in operations. Total assets were approximately $1.31 billion as of June 30, 2026, compared to $1.11 billion as of December 31, 2025. Total liabilities stood at $110.8 million as of June 30, 2026, up from $86.4 million as of December 31, 2025.

Collaboration Revenue

Collaboration revenue for the three months ended June 30, 2026, was $8.9 million, an increase from $6.6 million for the three months ended March 31, 2026. For the six months ended June 30, 2026, collaboration revenue totaled $15.4 million, compared to $0 for the same period in 2025. As of June 30, 2026, the remaining balance for research and development services performance obligations under the Servier exclusive license agreement for darovasertib was $147.0 million.

Operating Expenses

Research and Development (R&D) Expenses

R&D expenses for the three months ended June 30, 2026, were $108.7 million, up from $95.7 million for the three months ended March 31, 2026. For the six months ended June 30, 2026, R&D expenses totaled $204.4 million, an increase from $145.1 million for the six months ended June 30, 2025, primarily due to higher clinical trial and personnel-related expenses.

General and Administrative (G&A) Expenses

G&A expenses for the three months ended June 30, 2026, were $22.5 million, compared to $19.4 million for the three months ended March 31, 2026. For the six months ended June 30, 2026, G&A expenses were $41.8 million, up from $28.1 million for the same period in 2025, mainly attributed to higher personnel-related expenses and darovasertib commercial preparation activities.

Total Operating Expenses

Total operating expenses for the three months ended June 30, 2026, were $131.1 million, compared to $115.1 million for the three months ended March 31, 2026. For the six months ended June 30, 2026, total operating expenses were $246.3 million, up from $173.2 million for the six months ended June 30, 2025.

Profitability

Loss from Operations

The loss from operations was - $122.3 million for the three months ended June 30, 2026, and - $108.5 million for the three months ended March 31, 2026. For the six months ended June 30, 2026, the loss from operations was - $230.8 million, compared to - $173.2 million for the same period in 2025.

Interest Income and Other Income, Net

Interest income and other income, net, was $9.8 million for the three months ended June 30, 2026, and $10.0 million for the three months ended March 31, 2026. For the six months ended June 30, 2026, this amounted to $19.8 million, compared to $23.5 million for the six months ended June 30, 2025.

Net Loss

The net loss for the three months ended June 30, 2026, was - $112.5 million, compared to - $98.5 million for the three months ended March 31, 2026. For the six months ended June 30, 2026, the net loss was - $211.0 million, compared to - $149.7 million for the six months ended June 30, 2025.

Unrealized Losses (Gains) on Marketable Securities

Unrealized losses on marketable securities were - $1.2 million for the three months ended June 30, 2026, and - $2.8 million for the three months ended March 31, 2026. For the six months ended June 30, 2026, unrealized losses were - $3.9 million, compared to unrealized gains of $0.7 million for the same period in 2025.

Comprehensive Loss

The comprehensive loss was - $113.6 million for the three months ended June 30, 2026, and - $101.3 million for the three months ended March 31, 2026. For the six months ended June 30, 2026, the comprehensive loss was - $214.9 million, compared to - $149.0 million for the six months ended June 30, 2025.

Stock Compensation Expense

Total stock compensation expense for the three months ended June 30, 2026, was $16.7 million, compared to $14.5 million for the three months ended March 31, 2026.

Outlook / Guidance

IDEAYA Biosciences, Inc. maintains its cash runway guidance into 2030 based on its current operating plan, supported by approximately $1.24 billion in cash, cash equivalents, and marketable securities as of June 30, 2026. The company anticipates several key clinical updates throughout the remainder of 2026, including updated data for IDE849 at ESMO and the initiation of a Phase 1 combination trial for IDE892 with Roche in H2 2026. IDEAYA Biosciences, Inc. also plans to host an R&D Day in Q4 2026 focused on MTAP/CDKN2A, KRAS, and pancreatic cancer.